LMLLF (Pharmadrug) Shares Buyback Ratio %: -24.00 (As of Jul. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Pharmadrug Shares Buyback Ratio %?

Pharmadrug LMLLF Shares Buyback Ratio % is -24.00 as of Jul. 31, 2026. The stock has 1 warning sign investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Pharmadrug's current shares buyback ratio was -24.00%.

Pharmadrug Shares Buyback Ratio % Related Terms

Pharmadrug Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Pharmadrug's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmadrug Shares Buyback Ratio % Chart

Pharmadrug Annual Data
Trend Sep16 Sep17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -41.05 -4.35 -73.55 -22.19 -0.46

Pharmadrug Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.46 0.00 0.00 0.00 -24.00

Pharmadrug Shares Buyback Ratio % Calculation

Pharmadrug's Shares Buyback Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2024 ) - Shares Outstanding (EOP) (A: Dec. 2025 )) / Shares Outstanding (EOP) (A: Dec. 2024 )
=(107.734 - 108.234) / 107.734
=-0.46%

Pharmadrug's Shares Buyback Ratio for the quarter that ended in Mar. 2026 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2025 ) - Shares Outstanding (EOP) (A: Mar. 2026 )) / Shares Outstanding (EOP) (A: Dec. 2025 )
=(108.234 - 134.214) / 108.234
=-24.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -24.00 mean?
Pharmadrug (LMLLF) has a Shares Buyback Ratio % of -24.00 as of Jul. 31, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Pharmadrug and its competitors.
Is Pharmadrug's Shares Buyback Ratio % too high?
Pharmadrug's current Shares Buyback Ratio % is -24.00.
How does Pharmadrug's Shares Buyback Ratio % compare to ZTS?
Pharmadrug's Shares Buyback Ratio % of -24.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Drug Manufacturers company?
A good Shares Buyback Ratio % depends on the Drug Manufacturers industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Pharmadrug and its competitors. Pharmadrug's current Shares Buyback Ratio % is -24.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmadrug stock overvalued right now?
Based on GuruFocus' analysis, Pharmadrug (LMLLF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.04, compared to a current price of $0.01 — trading 84.4% below its estimated fair value. The current Shares Buyback Ratio % is -24.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Pharmadrug (LMLLF), the current Shares Buyback Ratio % is -24.00 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmadrug Business Description

Other Exchanges PHRX:Canada
Address 130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5K 1H1
Pharmadrug Inc is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally derived approved drugs. The company's operations comprise of the corporate division in Canada.